Company news

Akebia Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

March 18, 2025

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

March 18, 2025

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

March 12, 2025

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

March 5, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 3, 2025

Akebia Therapeutics Announces Multiple Positive Business Updates

January 12, 2025

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 17, 2024

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

December 2, 2024

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

November 24, 2024

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

November 13, 2024

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

November 11, 2024

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

November 6, 2024

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

October 31, 2024

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

October 21, 2024

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

October 14, 2024

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

October 9, 2024

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

October 6, 2024

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

September 4, 2024

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

August 7, 2024

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

August 1, 2024

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

July 10, 2024

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

June 26, 2024

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

June 23, 2024

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

May 22, 2024

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference

May 13, 2024

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 8, 2024

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights

May 1, 2024

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

March 26, 2024

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

March 13, 2024

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

March 10, 2024

Akebia Secures $55 Million Term Loan Financing

January 29, 2024

Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

January 8, 2024

Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

Akebia Therapeutics to Present at Piper Sandler Healthcare Conference

November 19, 2023

Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

November 7, 2023

Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors

November 1, 2023

Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights

October 30, 2023

Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease

October 24, 2023

Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023

October 17, 2023

Akebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat

September 27, 2023

Akebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update

September 25, 2023

Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference

September 5, 2023

Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 24, 2023

Akebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023

August 23, 2023

Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights

August 22, 2023

Akebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023

August 16, 2023

Akebia Therapeutics Provides Update on Form 10-Q Filing

August 9, 2023

Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference

July 18, 2023

Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023

July 17, 2023

Akebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients

June 28, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.